The role of metabolic disorders in the progression of renal dysfunction in patients with metabolic syndrome and arterial hypertension

Полозова, Э. И.; Сорокина, Н.; Пузанова, Е. В.; Сеськина, А. А.

doi:10.21518/2079-701x-2019-6-170-175

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Лептинорезистентность и гиперлептинемия способствуют развитию фиброза, повышению продукции коллагена I типа и пролиферации гладкомышечных клеток в почечных сосудах. Лептин повреждает почечные эндотелиоциты свободными радикалами кислорода, стимулирует выработку эндотелина-1 [80]. Высокое содержание в крови при ожирении свободных жирных кислот и триглицеридов -«сосудистая липотоксичность», содействуя продукции провоспалительных цитокинов, может оказывать самостоятельный нефротоксический эффект.…”

Section: ожирение и артериальная гипертензияunclassified

Obesity as a main component of metabolic syndrome and a risk factor for comorbidity

Sharonova,

Bulgakova,

Dolgikh

et al. 2024

ECG

View full text Add to dashboard Cite

Obesity is an important medical and social problem, it occupies one of the leading places among cardiovascular risk factors. Obesity is a major component of the metabolic syndrome. It has a close pathogenetic relationship with its other manifestations, as a result of which a portrait of a comorbid patient is formed. The article presents data on the prevalence, criteria for diagnosing obesity, the relationship of obesity with other components of the metabolic syndrome is shown. The role of adipose tissue dysfunction in obesity on the development and progression of insulin resistance, atherosclerosis, as well as its relationship with non-alcoholic fatty liver disease and arterial hypertension is discussed. It is shown that obesity is a comorbidity factor and the basis of the metabolic syndrome, the leading pathogenetic mechanism in the formation and progression of its components, preceding their occurrence. This allows us to conclude that weight loss can reduce cardiovascular risks, reduce the manifestations of the metabolic syndrome, and in some cases even eliminate them completely.

show abstract

Section: ожирение и артериальная гипертензияunclassified

Obesity as a main component of metabolic syndrome and a risk factor for comorbidity

Sharonova,

Bulgakova,

Dolgikh

et al. 2024

ECG

View full text Add to dashboard Cite

show abstract

Influence of Mirabegron, Adrenaline, and Ascorbic Acid on the Intensity of Iron-Induced Biochemiluminescence of Erythrocytes in Whole Blood in Men

Zavalin

Tsirkin²,

Morozova³

et al. 2022

Hum Physiol

View full text Add to dashboard Cite

Assessment of metabolic markers of cardiorenal disorders in patients with arterial hypertension and metabolic syndrome

Vlasova,

Seskina,

Myshkina

2024

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. Cardiorenal disorders (CRN) in arterial hypertension (AH) occur with interdependent dysfunction of the cardiovascular and renal systems. The concept of cardio-reno-metabolic health (CRMH) defines a dependent relationship between the clinical and pathogenetic manifestations of heart and kidney diseases in patients with metabolic disorders (MN).Aim. To study the metabolic markers of CRN in patients with hypertension and in combination with metabolic syndrome (MS).Materials and methods. The functions of the heart, kidneys, and lipid profile were studied in patients aged 40 to 69 years with hypertension and with hypertension in combination with MS.Results. The average eGFR values (estimated glomerular filtration rate) based on cystatin C are 53,5% lower than those based on creatinine (p = 0.0001). Patients with hypertension combined with MS were 42.7% more likely to have chronic kidney disease (CKD) C3aA2, 21.2% more likely to have C3bA2; the level of highly sensitive C–reactive protein (hs-CRP) was 42.8% higher compared with patients with hypertension without MN (p = 0.0001). Cystatin C values positively correlate with systolic blood pressure (SAD); eGFR has a negative association with SAD in both groups (p < 0.05). The presence of chronic heart failure with a low ejection fraction (CHF) in combination with chronic kidney disease (CKD) with moderate (C3a A2) and significantly reduced (C3b A2) renal function allows us to state the presence of CRN in 13.3% of patients with hypertension and in 17.7% of patients with hypertension combined with MS (p = 0.0001). Dyslipidemia and atherogenic lipid levels are 122% higher in patients with hypertension combined with MS, hyperlipoproteinemia (a) is 79% more common in patients with CRN on the background of MN (p = 0.0001).Conclusion. Elevated lipoprotein (a) (LP (a)) concentrations and dyslipidemia in patients with hypertension are associated with cardiorenal and metabolic disorders.

show abstract

The role of metabolic disorders in the progression of renal dysfunction in patients with metabolic syndrome and arterial hypertension

Cited by 3 publications

References 4 publications

Obesity as a main component of metabolic syndrome and a risk factor for comorbidity

Obesity as a main component of metabolic syndrome and a risk factor for comorbidity

Influence of Mirabegron, Adrenaline, and Ascorbic Acid on the Intensity of Iron-Induced Biochemiluminescence of Erythrocytes in Whole Blood in Men

Assessment of metabolic markers of cardiorenal disorders in patients with arterial hypertension and metabolic syndrome

Contact Info

Product

Resources

About